• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel

    1/5/22 8:00:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRDA alert in real time by email

    BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately.

    "We are thrilled to recognize the appointment of Jared to General Counsel," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Since joining Entrada, Jared has been critical in leading our legal and compliance functions, guiding us through our recent financings and building a robust patent estate covering our innovative EEV platform and associated programs. This appointment reflects his past contributions, and more importantly, our confidence in his potential to lead Entrada through our next phase of growth."

    Dr. Cohen has nearly 20 years of legal experience, with the majority of his career spent in the healthcare industry. Prior to joining Entrada in April 2020, Dr. Cohen was Vice President of Legal Affairs at Repertoire Immune Medicines where he designed and led all facets of the legal, compliance and intellectual property functions for the organization, including the transition through Series B, subsidiary acquisition and corporate merger. Prior to Repertoire, Dr. Cohen held a variety of leadership roles in the biopharmaceutical field, including Alexion Pharmaceuticals, The Jackson Laboratory, MedImmune/AstraZeneca, Human Genome Sciences, and Finnegan Henderson. Dr. Cohen earned his BS in Biology at Duke University, his PhD in Biochemistry, Molecular and Cell Biology from Cornell University and attended Cornell Law School.

    About Entrada Therapeutics

    Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).

    For more information about Entrada, please visit our website, www.entradatx.com, and follow us on Twitter and LinkedIn.

    Entrada/Investor Contact

    Karla MacDonald

    VP, Corporate Communications and Investor Relations

    [email protected]

    Media Contact

    Aulani Capuchin

    Real Chemistry

    [email protected]

    (559) 355-2673

     



    Primary Logo

    Get the next $TRDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRDA

    DatePrice TargetRatingAnalyst
    12/6/2024$29.00Buy
    ROTH MKM
    1/5/2024$22.00Outperform
    Oppenheimer
    4/3/2023$25.00Buy
    H.C. Wainwright
    11/24/2021Outperform
    Evercore ISI Group
    11/23/2021Outperform
    Cowen & Co.
    11/23/2021$29.00Neutral
    Goldman Sachs
    More analyst ratings

    $TRDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Kim Peter S bought $731,682 worth of shares (50,000 units at $14.63), increasing direct ownership by 74% to 117,412 units (SEC Form 4)

      4/A - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      6/18/25 4:32:46 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kim Peter S bought $364,672 worth of shares (25,000 units at $14.59), increasing direct ownership by 37% to 92,412 units (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      5/16/24 4:33:48 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kim Peter S bought $63,306 worth of shares (4,476 units at $14.14), increasing direct ownership by 7% to 67,412 units (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      5/10/24 4:35:37 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

      6/3/25 7:00:00 AM ET
      $BIIB
      $TRDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

      āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,

      9/17/24 8:30:00 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

      BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. "Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Wit

      8/10/23 7:00:00 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care